| Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation S Elf, NS Abdelfattah, E Chen, J Perales-Patón, EA Rosen, A Ko, ... Cancer discovery 6 (4), 368-381, 2016 | 270 | 2016 |
| T-Scan: a genome-wide method for the systematic discovery of T cell epitopes T Kula, MH Dezfulian, CI Wang, NS Abdelfattah, ZC Hartman, ... Cell 178 (4), 1016-1028. e13, 2019 | 187 | 2019 |
| Optimized cell transplantation using adult rag2 mutant zebrafish Q Tang, NS Abdelfattah, JS Blackburn, JC Moore, SA Martinez, FE Moore, ... Nature methods 11 (8), 821-824, 2014 | 138 | 2014 |
| Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN S Elf, NS Abdelfattah, AJ Baral, D Beeson, JF Rivera, A Ko, N Florescu, ... Blood, The Journal of the American Society of Hematology 131 (7), 782-786, 2018 | 88 | 2018 |
| TOX regulates growth, DNA repair, and genomic instability in T-cell acute lymphoblastic leukemia R Lobbardi, J Pinder, B Martinez-Pastor, M Theodorou, JS Blackburn, ... Cancer discovery 7 (11), 1336-1353, 2017 | 60 | 2017 |
| Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016; 6: 368–381. doi: 10.1158/2159-8290 S Elf, NS Abdelfattah, E Chen, J Perales-Patón, EA Rosen, A Ko, ... Go to original source... Go to PubMed, 2018 | 51 | 2018 |
| High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform PM Bruno, RT Timms, NS Abdelfattah, Y Leng, FJN Lelis, DR Wesemann, ... Nature biotechnology 41 (7), 980-992, 2023 | 12 | 2023 |
| Using CRISPR/cas9 gene editing to investigate the oncogenic activity of mutant calreticulin in cytokine dependent hematopoietic cells NS Abdelfattah, A Mullally JoVE (Journal of Visualized Experiments), e56726, 2018 | 6 | 2018 |
| Physical interaction between mutant calreticulin and the thrombopoietin receptor is required for hematopoietic transformation S Elf, N Abdelfattah, E Chen, J Perales-Patón, E Rosen, A Ko, F Peisker, ... Blood 126 (23), LBA-4, 2015 | 4 | 2015 |
| T-Switch: A specificity-based engineering platform for the development of T cell therapeutics NS Abdelfattah | | 2024 |
| 63 EpiScan: A synthetic biology platform for targeted immunopeptidomics P Bruno, R Timms, N Abdelfattah, Y Leng, F Lelis, D Wesemann, X Yu, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Thymocyte selection-associated HMG box protein (TOX) induces genomic instability in T-cell acute lymphoblastic leukemia R Lobbardi, J Pinder, B Martinez-Pastor, J Blackburn, BJ Abraham, ... Cancer Research 76 (14_Supplement), 3583-3583, 2016 | | 2016 |
| Thymocyte Selection-Associated High-Mobility Group Box Protein (TOX) Induces Genomic Instability in T-Cell Acute Lymphoblastic Leukemia R Lobbardi, J Pinder, B Martinez-Pastor, JS Blackburn, N Abdelfattah, ... Blood 124 (21), 475, 2014 | | 2014 |
| Abstract B30: A large-scale transgenic screen in zebrafish identifies TOX as a novel oncogene in T-cell acute lymphoblastic leukemia R Lobbardi, N Abdelfattah, B Martinez, J Pinder, D Toiber, JS Blackburn, ... Cancer Research 74 (20_Supplement), B30-B30, 2014 | | 2014 |
| Uncovering the role of HMG box protein TOX in T-cell Acute Lymphoblastic Leukemia (T-ALL) N Abdelfattah Harvard Medical School, 2013 | | 2013 |
| This is a repository copy of Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. S Elf, NS Abdelfattah, AJ Baral | | |
Edwin ChenHarvard UniversityVerified email at partners.org
